Newsfeeds - Spark Newswire

1 minute read

Matinas Biopharma Holdings Cash, Cash Equivalents And Marketable Securities As Of December 31, 2022 Were $28.8M Compared With $49.6M As Of December 31, 2021

Today, 7:34 PM

Cash, cash equivalents and marketable securities as of December 31, 2022 were $28.8 million compared with $49.6 million as of December 31, 2021. Based on current projections, the Company believes its

MTNB

7 minute read

Matinas BioPharma Provides Business Update And 2023 Strategic Outlook; Ended 2022 With ~$28.8M, Sufficient To Fund Planned Operations Into Q2 2024

By Happy Mohamed

Today, 7:34 PM

2022 Success Has Increased Confidence to Focus LNC Delivery Platform on the Future of Medicine - Delivering Genes Prioritization on Building External Partnerships and an Internal Pipeline Centered on Gene

MTNB

5 minute read

Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday

By Lisa Levin

Today, 7:34 PM

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.

ALF

7 minute read

Matinas BioPharma Announces Interim Data From The Phase 2 EnACT Trial Of MAT2203 For The Treatment Of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival In All-Oral Cohort 4 Regimen Currently 90%

By Benzinga Newsdesk

Today, 7:34 PM

Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 Mean Early Fungicidal Activity (EFA) of the rate of yeast clearance in cerebrospinal fluid exceeded

MTNB

1 minute read

Matinas BioPharma Hldgs Q2 EPS $(0.03), Inline

By Benzinga Newsdesk

Today, 7:34 PM

Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year.

MTNB

17 minute read

Earnings Scheduled For August 11, 2022

By Benzinga Insights

Today, 7:34 PM

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

AACG

2 minute read

Matinas BioPharma Announces Positive Opinion By The European Medicines Agency On Orphan Drug Designation For MAT2203 For The Treatment Of Cryptococcosis

By Benzinga Newsdesk

Today, 7:34 PM

Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform

MTNB